Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome
- PMID: 8742786
Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome
Abstract
The NOS inhibitors L-NARG and L-NAME attenuate weight loss and wet dog shakes, two specific signs of opioid withdrawal in rats. NMMA is more potent than L-NAME, consistent with the in vivo actions of these compounds as inhibitors of NOS. In addition, NMMA antagonizes naloxone-induced jumping in morphine-dependent rats. The NOS inhibitors generally increase teeth chattering in precipitated withdrawal. The profile of the diminished withdrawal signs produced by these drugs differs from that produced by clonidine, which stimulates locomotor activity and does not increase teeth chattering in precipitated opioid withdrawal (Kimes et al. 1990). These findings suggest that administration of inhibitors of NOS may be an effective treatment of the opioid withdrawal syndrome alone or in combination with clonidine (U.S. patent #5,225,40).
Similar articles
-
Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase.Psychopharmacology (Berl). 1993;112(4):521-4. doi: 10.1007/BF02244904. Psychopharmacology (Berl). 1993. PMID: 7532866
-
Effects of nitric oxide synthase inhibitors in attenuating nicotine withdrawal in rats.Pharmacol Biochem Behav. 2008 Feb;88(4):473-80. doi: 10.1016/j.pbb.2007.09.021. Epub 2007 Oct 22. Pharmacol Biochem Behav. 2008. PMID: 18031800
-
Inhibitory effect of nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawal syndrome in morphine-dependent mice.Neurosci Lett. 1993 Nov 12;162(1-2):97-100. doi: 10.1016/0304-3940(93)90569-7. Neurosci Lett. 1993. PMID: 7510058
-
Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal.Neuropsychopharmacology. 1995 Dec;13(4):315-22. doi: 10.1016/0893-133X(95)00138-4. Neuropsychopharmacology. 1995. PMID: 8747756 Review.
-
Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance.Neuropsychopharmacology. 1995 Dec;13(4):309-13. doi: 10.1016/0893-133X(95)00084-Q. Neuropsychopharmacology. 1995. PMID: 8747755 Review.
Cited by
-
Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat.J Neurosci. 1997 Oct 15;17(20):8018-23. doi: 10.1523/JNEUROSCI.17-20-08018.1997. J Neurosci. 1997. PMID: 9315920 Free PMC article.
-
Lipophilic analogues of D-cysteine prevent and reverse physical dependence to fentanyl in male rats.Front Pharmacol. 2024 Apr 5;14:1336440. doi: 10.3389/fphar.2023.1336440. eCollection 2023. Front Pharmacol. 2024. PMID: 38645835 Free PMC article.
-
Nitric oxide inhibition strategies.Future Sci OA. 2015;1(1):FSO35. doi: 10.4155/fso.15.35. Future Sci OA. 2015. PMID: 26634146 Free PMC article.
-
The epigenetic signatures of opioid addiction and physical dependence are prevented by D-cysteine ethyl ester and betaine.Front Pharmacol. 2024 Aug 30;15:1416701. doi: 10.3389/fphar.2024.1416701. eCollection 2024. Front Pharmacol. 2024. PMID: 39281282 Free PMC article.
-
Hyperbaric oxygen treatment suppresses withdrawal signs in morphine-dependent mice.Brain Res. 2016 Oct 1;1648(Pt A):434-437. doi: 10.1016/j.brainres.2016.08.017. Epub 2016 Aug 14. Brain Res. 2016. PMID: 27534375 Free PMC article.